Mridu Gulati, MD, MPH
Associate Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine)Cards
About
Research
Publications
2025
The Future of Precision Medicine in Interstitial Lung Disease
Adams T, Patel C, Gulati M. The Future of Precision Medicine in Interstitial Lung Disease. Respiratory Medicine 2025, 195-212. DOI: 10.1007/978-3-031-87183-2_11.ChaptersHypersensitivity pneumonitis associated with home mold exposure: A retrospective cohort analysis
Adams T, Redlich C, Glazer C, Gulati M. Hypersensitivity pneumonitis associated with home mold exposure: A retrospective cohort analysis. PLOS ONE 2025, 20: e0323093. PMID: 40338891, PMCID: PMC12061107, DOI: 10.1371/journal.pone.0323093.Peer-Reviewed Original ResearchConceptsDiagnosis of HPHP patientsRetrospective cohort of patientsMold exposureTransplant free survivalCohort of patientsRetrospective cohort analysisMedical chart reviewDevelopment of HPHypersensitivity pneumonitis patientsHome moldFibrotic HPFree survivalAntigen exposureChart reviewConfident diagnosisRetrospective cohortPneumonic patientsInvasive proceduresHypersensitivity pneumonitisCohort analysisCulprit antigenPatientsImprove outcomesCohortLong-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
Sack C, Wojdyla D, MacMurdo M, Gassett A, Kaufman J, Raghu G, Redlich C, Li P, Olson A, Leonard T, Todd J, Neely M, Snyder L, Gulati M. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Annals Of The American Thoracic Society 2025, 22: 378-386. PMID: 39531618, DOI: 10.1513/annalsats.202404-382oc.Peer-Reviewed Original ResearchAssociated with worse qualityExposure to air pollutionGene-environment interactionsQuality of lifePollution exposureEffects of long-term exposure to air pollutionLong-term exposure to PM2.5 anLong-term exposure to air pollutionWorse qualityParticipant's residential addressQuality of life measuresNon-Hispanic whitesExposure to PM2.5Multi-pollutant modelsYears of follow-upCox proportional hazards modelsLower FVC %Residential addressesProportional hazards modelIPF-PRO RegistryMultivariate regression modelEffect modificationEuroQol scoresLife measuresEnrollment dateChanges in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis
Oldham J, Neely M, Wojdyla D, Gulati M, Li P, Patel D, Palmer S, Todd J, Investigators I. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest 2025, 168: 415-422. PMID: 40020995, DOI: 10.1016/j.chest.2025.02.018.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisLung transplantationLung function declinePulmonary fibrosisAssociated with 1.8-foldProgressive fibrosing interstitial lung diseaseMedian follow-up timeFibrosing interstitial lung diseaseFollow-up timeInterstitial lung diseaseCox proportional hazards modelsRisk of deathFunctional declineRisk of mortalityProportional hazards modelAntifibrotic treatmentThreshold of declineAssociated with lung function declineOutcomes RegistryLung diseaseEnrolling centersDLCOSmoking statusDiffusing capacityLung function
2024
Plasma collagen neoepitopes are associated with multiorgan disease in the ACCESS and GRADS sarcoidosis cohorts
Sand J, Jessen H, Leeming D, Yu S, Lee C, Hu B, Sun Y, Adams T, Pivarnik T, Liu A, Woo S, McGovern J, Fiorini V, Saber T, Higuero-Sevilla J, Gulati M, Kaminski N, Damsky W, Shaw A, Mohanty S, Goobie G, Zhang Y, Herzog E, Ryu C. Plasma collagen neoepitopes are associated with multiorgan disease in the ACCESS and GRADS sarcoidosis cohorts. Thorax 2024, 79: 1136-1144. PMID: 39117421, PMCID: PMC12147189, DOI: 10.1136/thorax-2023-221095.Peer-Reviewed Original ResearchSarcoidosis cohortMultiorgan diseasePRO-C3Interleukin-4Case Control Etiologic Study of SarcoidosisPlasma levels of interleukin-4Alpha-1 antitrypsin deficiencyLevels of interleukin-4Pathogenesis of sarcoidosisC6MC3MHealthy control patientsStudy of sarcoidosisGenomic researchAbnormal extracellular matrixAssociated with dermatological diseaseCollagen degradationScadding stageCorticosteroid useComplex diseasesPRO-C6Control patientsIL-13IL-5IL-9Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease
Swaminathan A, McFatrich M, Mkumba L, Wright L, Redlich C, Snyder L, Reeve B, Patel D, Gulati M. Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease. Respiratory Research 2024, 25: 372. PMID: 39407223, PMCID: PMC11481565, DOI: 10.1186/s12931-024-03000-z.Peer-Reviewed Original ResearchConceptsCognitive interviewsContent validityExposure questionnaireMultidisciplinary teamSemi-structured interview guideEvidence of content validityFibrosing ILDsInterstitial lung diseaseRelevant exposuresFibrotic interstitial lung diseaseClinically relevant exposuresTrained interviewersInterview guideAssessment QuestionnaireQuestionnaireInterviewsLung diseaseAdultsTeamClinicPatientsSource of misunderstandingOccupational inhalation exposureValidityDisease
2023
Circulating Mitochondrial DNA Is Associated With High Levels of Fatigue in Two Independent Sarcoidosis Cohorts
Fiorini V, Hu B, Sun Y, Yu S, McGovern J, Gandhi S, Woo S, Turcotte-Foster S, Pivarnik T, Khan Z, Adams T, Herzog E, Kaminski N, Gulati M, Ryu C. Circulating Mitochondrial DNA Is Associated With High Levels of Fatigue in Two Independent Sarcoidosis Cohorts. Chest 2023, 165: 1174-1185. PMID: 37977267, PMCID: PMC11110677, DOI: 10.1016/j.chest.2023.11.020.Peer-Reviewed Original ResearchPatient-related outcome measuresToll-like receptor 9Fatigue Assessment ScalePlasma mtDNA concentrationsTLR9 activationSarcoidosis patientsMtDNA concentrationsMulti-organ sarcoidosisCommon chief complaintInnate immune activationNovel therapeutic strategiesDomains of fatigueSevere clinical phenotypePsychobiologic mechanismsSarcoidosis cohortScadding stageCorticosteroid useCytokine levelsExtrapulmonary diseaseProspective cohortFAS scoresPulmonary fibrosisChief complaintImmune activationPatient populationProteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome
Singh I, Leitner B, Wang Y, Zhang H, Joseph P, Lutchmansingh D, Gulati M, Possick J, Damsky W, Hwa J, Heerdt P, Chun H. Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome. Pulmonary Circulation 2023, 13: e12220. PMID: 37091121, PMCID: PMC10113513, DOI: 10.1002/pul2.12220.Peer-Reviewed Original ResearchInvasive cardiopulmonary exercise testPASC patientsPost-acute sequelaeAcute sequelaeInfection syndromeUnexplained exertional intoleranceCardiopulmonary exercise testSystemic oxygen deliveryPersistent inflammatory stateVenous blood plasmaExertional intolerancePeak exerciseEndothelial dysfunctionHemodynamic profileInflammatory stateExercise testFibrotic processPathophysiological hallmarkAberrant protein expressionExpression of proteinsOxygen deliveryOxygen extractionProteomic profilingPatientsPhysiologic responsesAutoimmune comorbidities associated with sarcoidosis: a case-control study in the All of Us research program
Murphy M, Edemobi P, Leasure A, Gulati M, Miller E, Damsky W, Cohen J. Autoimmune comorbidities associated with sarcoidosis: a case-control study in the All of Us research program. Rheumatology Advances In Practice 2023, 7: rkad030. PMID: 38606002, PMCID: PMC11007907, DOI: 10.1093/rap/rkad030.Peer-Reviewed Original ResearchCase-control studyAutoimmune diseasesSarcoidosis patientsMultivariable analysisOdds ratioSarcoidosis casesUs Research ProgramDiverse cohortConcomitant autoimmune diseasesRace-matched controlsMultiple autoimmune diseasesAutoimmune comorbiditiesSarcoidosisPatientsLogistic regressionDiseaseSmall sample sizeCareful screeningCohortAssociationSample sizeComposite variablePrior studiesComorbiditiesStudy“Long Haulers”
Lutchmansingh D, Sevilla J, Possick J, Gulati M. “Long Haulers”. Seminars In Respiratory And Critical Care Medicine 2023, 44: 130-142. PMID: 36646091, DOI: 10.1055/s-0042-1759568.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPost-COVID conditionsAcute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSARS-CoV-2 infectionChronic COVID-19Long-haul COVIDOngoing interventional trialsLong-term morbidityCoronavirus disease 2019Multiple organ systemsInterventional trialsLong COVIDTreatment algorithmNeuropsychiatric sequelaePostacute sequelaeRisk factorsObservational studyDisease 2019Long-term effectsSurvivors' qualityClinical protocolsLong haulersOrgan systems
Clinical Trials
Current Trials
Genetic Determinants of Aneurysms in Autosomal Dominant Polycystic Kidney Disease
IRB ID2000029350RoleSub InvestigatorPrimary Completion Date12/31/2022Recruiting ParticipantsGenderBothAge18+ yearsPathogenic Wnt-beta catenin target genes in macrophages and fibrosis
IRB ID2000024862RoleSub InvestigatorPrimary Completion Date12/31/2023Recruiting Participants
Clinical Care
Overview
Mridu Gulati, MD, is a pulmonologist and critical care specialist who also focuses on occupational and environmental lung diseases. She cares for people with interstitial lung disease (a group of conditions that cause scarring in the lungs) and sarcoidosis (an inflammatory disease that can affect multiple organs, especially the lungs).
An associate professor of medicine (pulmonary, critical care and sleep medicine) at Yale School of Medicine, Dr. Gulati earned her medical degree from New York University. After completing a residency in internal medicine at the University of Michigan Medical Center, she pursued fellowships in pulmonary and critical care at Yale School of Medicine the University of California, San Francisco and New York University School of Medicine.
Clinical Specialties
Occupational Health & Environmental Medicine; Pulmonology & Sleep Medicine; Pulmonary Critical Care
Fact Sheets
Interstitial Lung Disease (ILD)
Learn More on Yale MedicineSarcoidosis
Learn More on Yale MedicineDyspnea with Advanced Cancers
Learn More on Yale MedicineAnesthesia for Organ Transplant
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
Get In Touch
Contacts
Academic Office Number
Appointment Number
Office Fax Number
Clinic Fax Number
Mailing Address
Pulmonary, Critical Care & Sleep Medicine
PO Box 208057, 300 Cedar Street
New Haven, CT 06520-8057
United States
Locations
Lippard Laboratory of Clinical Investigation (LLCI)
Academic Office
15 York Street, Ste 101D
New Haven, CT 06510
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.